APx Acquisition Corp. I
11.90+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · APXIF · USD
Key Stats
Market Cap
57.51MP/E (TTM)
-Basic EPS (TTM)
-0.54Dividend Yield
0%Recent Filings
10-Q
Q1 FY2025 results
APX Acquisition Corp. I posted a net loss of $3.7M for Q1 2025 ended March 31, up from $2.2M a year earlier, driven by a $3.3M unrealized loss on warrant liabilities that more than offset $65.5K in trust interest income and $351.5K operating expenses. Operating loss narrowed to $351.5K from $1.3M y/y, reflecting tighter cost controls amid the hunt for a business combination. Diluted EPS fell to $(0.76) across 4.8M weighted shares, consistent for redeemable and non-redeemable classes with no anti-dilution effects. Cash dwindled to $72 while trust assets grew to $6.3M; total debt hit $2.9M including $1.5M convertible notes and $1.4M promissory notes at 20% rates due at merger close. The proposed merger with OmnigenicsAI advances, backed by a $10M commitment, yet Nasdaq delisting to OTC markets adds friction. Warrant volatility swings hard.
10-K
FY2024 results
APx Acquisition Corp. I, a blank check company, reported no operating revenues for FY2024 ended December 31, 2024, with net loss of $119,057 driven by $2.6M in operating costs offset by $3.1M interest income from Trust Account investments holding $62.4M at year-end, down from prior extensions due to redemptions. Q4 saw continued momentum in pursuing the proposed merger with OmnigenicsAI, extended to December 2025 via shareholder vote with no further payments needed, while liquidity strained with $120 cash and $4.8M working capital deficit funded by $1.7M sponsor note and $0.9M Bioceres debt. No capex or dividends occurred, but delisting from Nasdaq in December 2024 risks quarterly trading liquidity. Yet the Trust remains intact at ~$12.05 per share. Sponsors control 89% of shares, ensuring alignment on the deal.
8-K
Nasdaq delisting hits APX
APX Acquisition Corp. I faces Nasdaq delisting after missing its 36-month deadline to complete an initial business combination by December 6, 2024, with trading suspended on December 17. Yet the planned merger with Omnigenics AI Corp presses on unaffected. Delisting stings, but OTC trading awaits. Forward-looking risks loom in SEC filings.
8-K
SPAC deadline extended
APx Acquisition Corp. I extended its deadline for completing a business combination to December 9, 2025, after shareholders approved amendments to the charter and trust agreement on December 4, 2024. While 5,077,568 public shares were redeemed, draining $60.9 million from the trust, $6.2 million remains to fund ongoing operations. This buys time. The firm also lifted net tangible asset restrictions to dodge penny stock rules.
10-Q
Q3 FY2024 results
APX Acquisition Corp. I swung to a Q3 net income of $2.1M, up sharply from $3.6M a year earlier, thanks to a $2.0M gain on warrant fair value changes that offset $0.7M in formation costs, while interest income from the Trust Account climbed to $0.8M from $0.6M (derived). Yet YTD through September 30, 2024, net income dipped to $0.3M versus $3.5M last year, as operating expenses doubled to $2.2M amid pursuit of a business combination with OmnigenicsAI, signed March 25, 2024, for a merger without MultiplAI after its August termination. Trust assets grew to $65.9M at $11.82 per redeemable share, bolstered by extensions to December 9, 2024, but cash dwindled to $168 with $4.8M in liabilities including $1.5M convertible notes. Warrants face delisting risk by December 6, 2024, per Nasdaq notice.
AACI
Armada Acquisition Corp. II
10.29-0.01
AIMTF
Aimfinity Investment Corp. I
7.07-4.03
APAD
A Paradise Acquisition Corp.
9.97-0.01
ASPC
A SPAC III Acquisition Corp.
10.37-0.14
AXIN
Axiom Intelligence Acquisition
10.07+0.02
CSTAF
Constellation Acquisition Corp
11.52+0.00
IBAC
IB Acquisition Corp.
10.44-0.01
IXAQF
IX Acquisition Corp.
12.20+0.00
SIMA
SIM Acquisition Corp. I
10.54+0.00
SPKL
Spark I Acquisition Corp.
11.37-0.18